Abstract
Purpose of Review
In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors.
Recent Findings
The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development. TrkA, B, and C are encoded by NTRK1, 2, and 3, respectively. NTRK chromosomal alterations, most commonly gene fusions, have been identified as driver mutations in a broad range of malignancies. Small molecule tyrosine kinase inhibitors of Trk, including larotrectinib, have shown broad clinical activity across multiple tumor types with NTRK fusion events.
Summary
Although the prevalence of NTRK alterations is low, the exceptional activity of larotrectinib makes NTRK alterations an important predictive biomarker to screen for in any cancer.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci. 2006;63(13):1523–37.
Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169(2):107–14.
Klein R, Jing SQ, Nanduri V, O’Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1):189–97.
Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24(23):5807–14.
Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350(6314):158–60.
Kawamura K, Kawamura N, Fukuda J, Kumagai J, Hsueh AJW, Tanaka T. Regulation of preimplantation embryo development by brain-derived neurotrophic factor. Dev Biol. 2007;311(1):147–58.
Kawamura K, Kawamura N, Sato W, Fukuda J, Kumagai J, Tanaka T. Brain-derived neurotrophic factor promotes implantation and subsequent placental development by stimulating trophoblast cell growth and survival. Endocrinology. 2009;150(8):3774–82.
Kawamura K, Kawamura N, Kumazawa Y, Kumagai J, Fujimoto T, Tanaka T. Brain-derived neurotrophic factor/tyrosine kinase B signaling regulates human trophoblast growth in an in vivo animal model of ectopic pregnancy. Endocrinology. 2011;152(3):1090–100.
Loeb DM, Stephens RM, Copeland T, Kaplan DR, Greene LA. A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth. J Biol Chem. 1994;269(12):8901–10.
Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66.
Miranda C, Mazzoni M, Sensi M, Pierotti MA, Greco A. Functional characterization of NTRK1 mutations identified in melanoma. Genes Chromosom Cancer. 2014;53(10):875–80.
Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 2004;6(4):347–60.
Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.
Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321(1):44–9.
Rubin JB, Segal RA. Growth, survival and migration: the Trk to cancer. Cancer Treat Res. 2003;115:1–18.
Sigal DS, Bhangoo MS, Hermel JA, Pavlick DC, Frampton G, Miller VA, et al. Comprehensive genomic profiling identified novel NTRK fusions in neuroendocrine tumors. Oncotarget. 2018;9(88):35809–12.
Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017;35(18_suppl):LBA2501.
Chen Y, Chi P. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 2018 7 [cited 2018 Aug 28];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992878/
• Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, et al. Activity of entrectinib in a patient with the first reported NTRK fusion in neuroendocrine cancer. J Natl Compr Cancer Netw. 2017;15(11):1317–22 This paper highlights the utility of NTRK inhibition in a patient with metastatic neuroendocrine tumor, a tumor type not previously known to exhibit targetable driver mutations.
Liu D, Offin M, Harnicar S, Li BT, Drilon A. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018;14:1247–52.
• Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367–76 This report characterizes the molecular pathogenesis of a secretory breast carcinoma, a rare histologic subtype associated with a TRK fusion event.
Watanabe N, Kobayashi H, Hirama T, Kikuta A, Koizumi S, Tsuru T, et al. Cryptic t(12;15)(p13;q26) producing the ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in congenital mesoblastic nephroma with trisomy 11: fluorescence in situ hybridization and IGF2 allelic expression analysis. Cancer Genet Cytogenet. 2002;136(1):10–6.
Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184–7.
Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049–57.
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–72.
Hong DS, Brose MS, Doebele RC, Shaw AT, Dowlati A, Bauer TM, et al. Abstract PR13: clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Mol Cancer Ther. 2015;14(12 Supplement 2):PR13.
Burris HA, Shaw AT, Bauer TM, Farago AF, Doebele RC, Smith S, et al. Abstract 4529: pharmacokinetics (PK) of LOXO-101 during the first-in-human phase I study in patients with advanced solid tumors: interim update. Cancer Res. 2015;75(15 Supplement):4529.
Bhangoo MS, Boasberg P, Mehta P, Elvin JA, Ali SM, Wu W, et al. Tumor mutational burden guides therapy in a treatment refractory POLE-mutant uterine carcinosarcoma. Oncologist. 2018;23(5):518–23.
Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, et al. Biallelic deletion of PALB2 occurs across multiple tumor types and suggests responsiveness to poly (ADP-ribose) polymerase inhibition. JCO Precis Oncol. 2017;1:1–7.
Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, et al. Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma. JCO Precis Oncol. 2017. https://doi.org/10.1200/PO.17.00034.
Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, Pappo A. Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer. 2016;63(8):1468–70.
Hong DS, Dowlati A, Burris HA III, Lee JJ, Brose MS, Farago AF, et al. Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Eur J Cancer. 2017;72:S148.
Ziegler DS, Wong M, Mayoh C, Kumar A, Tsoli M, Mould E, et al. Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br J Cancer. 2018;119(6):693–6.
DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, et al. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018;124(21):4241–7.
•• Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9 Landmark study reporting the safety and efficacy results of three early-phase clinical trials utilizing larotrectinib across multiple tumor types (pediatric and adults).
Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–72.
Zhai D, Deng W, Huang J, Rogers E, Cui JJ. Abstract 3161: TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling. Cancer Res. 2017;77(13 Supplement):3161.
Kozaki R, Yoshizawa T, Tsukamoto K, Kato H, Kawabata K. Abstract 2954A: a potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants. Cancer Res. 2016 Jul 15;76(14 Supplement):2954A.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–47.
•• Benayed R, Offin MD, Mullaney KA, Sukhadia P, Rios KM, Desmeules P, et al. Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays. J Clin Oncol. 2018;36(15_suppl):12076 This study emphasizes the sensitivity of RNA sequencing techniques which may identify TRK fusions not seen with conventional DNA sequencing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Munveer S. Bhangoo declares that he has no conflict of interest.
Darren Sigal has a patent issued on a method of treating neuroendocrine tumors.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Evolving Therapies
Rights and permissions
About this article
Cite this article
Bhangoo, M.S., Sigal, D. TRK Inhibitors: Clinical Development of Larotrectinib. Curr Oncol Rep 21, 14 (2019). https://doi.org/10.1007/s11912-019-0761-y
Published:
DOI: https://doi.org/10.1007/s11912-019-0761-y